Literature DB >> 18696129

Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis.

Elena Cichero1, Giulia Menozzi, Andrea Spallarossa, Luisa Mosti, Paola Fossa.   

Abstract

In order to elucidate the structural requirements for human CB(1) receptor antagonism, 78 antagonists belonging to five different chemical classes were selected from the literature and docked into the receptor binding site, built by homology modeling techniques. To further explore the structure-activity relationships within the considered chemical classes, a pharmacophore model and a QSAR analysis were developed. In a first step five alignments, one for each group of compounds were generated. All of them were then submitted to a MOE pharmacophore search in order to obtain a final pharmacophore model representative of the whole dataset which was used to elaborate the following 3D-QSAR analysis, by means of the CoMFA methodology. The results of these investigations are expected to be useful in the process of design and development of new potent CB(1) antagonists.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18696129     DOI: 10.1007/s00894-008-0356-2

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  14 in total

1.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

Authors:  R D Cramer; D E Patterson; J D Bunce
Journal:  J Am Chem Soc       Date:  1988-08-01       Impact factor: 15.419

Review 2.  The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.

Authors:  Didier M Lambert; Christopher J Fowler
Journal:  J Med Chem       Date:  2005-08-11       Impact factor: 7.446

3.  The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: application to a lead optimization of a human A3 adenosine receptor antagonist.

Authors:  Stefano Moro; Magdalena Bacilieri; Barbara Cacciari; Chiara Bolcato; Claudia Cusan; Giorgia Pastorin; Karl-Norbert Klotz; Giampiero Spalluto
Journal:  Bioorg Med Chem       Date:  2006-03-29       Impact factor: 3.641

4.  Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.

Authors:  Roger A Smith; Zahra Fathi; Su-Ellen Brown; Soongyu Choi; Jianmei Fan; Susan Jenkins; Harold C E Kluender; Anish Konkar; Rico Lavoie; Ronald Mays; Jennifer Natoli; Stephen J O'Connor; Astrid A Ortiz; Brent Podlogar; Christy Taing; Susan Tomlinson; Theresa Tritto; Zhonghua Zhang
Journal:  Bioorg Med Chem Lett       Date:  2006-11-02       Impact factor: 2.823

5.  Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.

Authors:  Helen E Armstrong; Amy Galka; Linus S Lin; Thomas J Lanza; James P Jewell; Shrenik K Shah; Ravi Guthikonda; Quang Truong; Linda L Chang; Grace Quaker; Vincent J Colandrea; Xinchun Tong; Junying Wang; Sherry Xu; Tung M Fong; Chun-Pyn Shen; Julie Lao; Jing Chen; Lauren P Shearman; D Sloan Stribling; Kimberly Rosko; Alison Strack; Sookhee Ha; Lex Van der Ploeg; Mark T Goulet; William K Hagmann
Journal:  Bioorg Med Chem Lett       Date:  2007-02-02       Impact factor: 2.823

Review 6.  CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications.

Authors:  Nadine Jagerovic; Cristina Fernandez-Fernandez; Pilar Goya
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

7.  Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors.

Authors:  Jean Mario Mussinu; Stefania Ruiu; Antonio C Mulè; Amedeo Pau; Mauro A M Carai; Giovanni Loriga; Gabriele Murineddu; Gérard A Pinna
Journal:  Bioorg Med Chem       Date:  2003-01-17       Impact factor: 3.641

8.  3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.

Authors:  Jian-Zhong Chen; Xiu-Wen Han; Qian Liu; Alexandros Makriyannis; Junmei Wang; Xiang-Qun Xie
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

9.  An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.

Authors:  Sean D McAllister; Gulrukh Rizvi; Sharon Anavi-Goffer; Dow P Hurst; Judy Barnett-Norris; Diane L Lynch; Patricia H Reggio; Mary E Abood
Journal:  J Med Chem       Date:  2003-11-20       Impact factor: 7.446

10.  Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716).

Authors:  Maria Elena Y Francisco; Herbert H Seltzman; Anne F Gilliam; René A Mitchell; Sharyl L Rider; Roger G Pertwee; Lesley A Stevenson; Brian F Thomas
Journal:  J Med Chem       Date:  2002-06-20       Impact factor: 7.446

View more
  1 in total

1.  New Insights into the Binding Features of F508del CFTR Potentiators: A Molecular Docking, Pharmacophore Mapping and QSAR Analysis Approach.

Authors:  Giada Righetti; Monica Casale; Michele Tonelli; Nara Liessi; Paola Fossa; Nicoletta Pedemonte; Enrico Millo; Elena Cichero
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.